Erlander
Principal executive officer pay for Erlander, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Cardiff Oncology, Inc. (CRDF) FY2021–FY2025
Aligned: paid up as stock roseCAP -$1,401,408→$890,939 while $100 invested went $33.00→$201.00
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2021 | $3.6M | -$1.4M |
| FY2022 | $1.6M | $91,869 |
| FY2023 | $1.5M | $1.4M |
| FY2024 | $2.4M | $4.7M |
| FY2025 | $3.0M | $890,939 |
The company's "$100 invested" index ran $33.00 at FY2021 → $201.00 by FY2025 — an annualized return of 57.1%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 57.1%/yr at CRDF ( FY2021–FY2025). See the CEO track-record ranking for context.